Literature DB >> 18684130

Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease.

Nobito Higuchi1, Masaki Kato, Yuki Shundo, Hirotaka Tajiri, Masatake Tanaka, Naoki Yamashita, Motoyuki Kohjima, Kazuhiro Kotoh, Makoto Nakamuta, Ryoichi Takayanagi, Munechika Enjoji.   

Abstract

AIM: Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of liver dysfunction and its incidence has increased markedly. However, the mechanisms involved in the pathogenesis of NAFLD in humans have not been thoroughly investigated. Sterol regulatory element binding protein (SREBP)-1c and carbohydrate responsive element binding protein (ChREBP) are transcriptional factors that regulate the expression of lipogenic genes, including acetyl-CoA carboxylases (ACCs) and fatty acid synthase (FAS). SREBP-1c and ChREBP are transactivated by liver X receptor (LXR), a nuclear receptor that regulates the metabolism of cholesterol and fatty acids. To understand the mechanisms involved in the pathogenesis of NAFLD, we investigated the transcriptional factors and lipogenic genes activated in the liver with NAFLD.
METHODS: Real-time PCR was carried out on liver biopsy samples from 20 NAFLD patients. The target genes studied were: ACC1, FAS, SREBP-1c, ChREBP, AMP-activated protein kinase (AMPK), and LXRalpha.
RESULTS: LXRalpha, SREBP-1c, ACC1, and FAS were upregulated in NAFLD patients. Expression levels of LXR were four times greater than those of the controls and correlated significantly with SREBP-1c, but not with ChREBP, levels.
CONCLUSIONS: These findings suggest that LXR acts as one of the main regulators of lipid metabolism by regulating SREBP-1c expression in NAFLD.

Entities:  

Year:  2008        PMID: 18684130     DOI: 10.1111/j.1872-034X.2008.00382.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  75 in total

Review 1.  Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?

Authors:  Munechika Enjoji; Makoto Nakamuta
Journal:  World J Gastroenterol       Date:  2010-02-21       Impact factor: 5.742

2.  Nonalcoholic fatty liver disease: from lipid profile to treatment.

Authors:  Kouichi Miura; Hirohide Ohnishi
Journal:  Clin J Gastroenterol       Date:  2012-06-17

3.  Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.

Authors:  Ahmed Aljohani; Mohammad Imran Khan; Abram Bonneville; Changan Guo; Justin Jeffery; Lucas O'Neill; Deeba Nadeem Syed; Sarah A Lewis; Maggie Burhans; Hasan Mukhtar; James M Ntambi
Journal:  J Biol Chem       Date:  2019-11-05       Impact factor: 5.157

4.  Dansameum regulates hepatic lipogenesis and inflammation in vitro and in vivo.

Authors:  Sang Hyun Ahn; Kang Pa Lee; Kibong Kim; Jun-Yong Choi; Sun-Young Park; Jin Hong Cheon
Journal:  Food Sci Biotechnol       Date:  2019-02-14       Impact factor: 2.391

5.  Nogo-B receptor deficiency increases liver X receptor alpha nuclear translocation and hepatic lipogenesis through an adenosine monophosphate-activated protein kinase alpha-dependent pathway.

Authors:  Wenquan Hu; Wenwen Zhang; Yuanli Chen; Ujala Rana; Ru-Jeng Teng; Yajun Duan; Zhong Liu; Baofeng Zhao; Jamie Foeckler; Hartmut Weiler; Rachel E Kallinger; Michael J Thomas; Kezhong Zhang; Jihong Han; Qing Robert Miao
Journal:  Hepatology       Date:  2016-08-23       Impact factor: 17.425

Review 6.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Authors:  Thomas Greuter; Harmeet Malhi; Gregory J Gores; Vijay H Shah
Journal:  JCI Insight       Date:  2017-09-07

Review 7.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

8.  Beneficial effects of flaxseed oil and fish oil diet are through modulation of different hepatic genes involved in lipid metabolism in streptozotocin-nicotinamide induced diabetic rats.

Authors:  Prasad P Devarshi; Nivedita M Jangale; Arvindkumar E Ghule; Subhash L Bodhankar; Abhay M Harsulkar
Journal:  Genes Nutr       Date:  2012-12-07       Impact factor: 5.523

9.  NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.

Authors:  Munechika Enjoji; Kazuyuki Machida; Motoyuki Kohjima; Masaki Kato; Kazuhiro Kotoh; Kazuhisa Matsunaga; Manabu Nakashima; Makoto Nakamuta
Journal:  Lipids Health Dis       Date:  2010-03-12       Impact factor: 3.876

Review 10.  Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Authors:  Kristina Blaslov; Tomislav Bulum; Karin Zibar; Lea Duvnjak
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.